Viewing data from:

OCUPRESS

NDA

CARTEOLOL HYDROCHLORIDE | N019972 | NOVARTIS PHARMACEUTICALS CORP

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain1 active DMF2 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

LUSOCHIMICA SPACARTEOLOL HYDROCHLORIDE

DMF 125091997

EDMOND PHARMAInactiveCARTEOLOL HYDROCHLORIDE

DMF 127141997

AMSA SPAInactiveCARTEOLOL HYDROCHLORIDE

DMF 149462000

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▴

SOLUTION/DROPS;OPHTHALMIC | Approved: May 23, 1990

No patent or exclusivity listings for this strength.